ROY DEL-ROSARIO: Open Payments
NPI 1740381870 · LANCASTER, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,859 in 165 payments from 15 companies in 2025. Trend: 2023 $3,104 · 2024 $2,782 · 2025 $2,859
Food & beverage: $2,859
| Company | Payments | Amount |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 29 | $549 |
| Alkermes, Inc. | 27 | $398 |
| Otsuka America Pharmaceutical, Inc. | 22 | $385 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 18 | $284 |
| Lundbeck LLC | 13 | $226 |
| E.R. Squibb & Sons, L.L.C. | 12 | $216 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $154 |
| ABBVIE INC. | 10 | $144 |
| Teva Pharmaceuticals USA, Inc. | 5 | $141 |
| Neurocrine BioSciences, Inc. | 5 | $102 |
Products named: REXULTI, Qelbree, ARISTADA, CAPLYTA, COBENFY, TRINTELLIX, VRAYLAR, INGREZZA.
Industry payments across CA — which companies pay providers there.
